Related Experiment Video

Updated: May 6, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

12.5K

Prostaglandins and prostaglandin inhibitors in ischemic heart disease

B Pitt, M J Shea, J L Romson

    Annals of Internal Medicine
    |July 1, 1983
    PubMed

    Insights

    The prostaglandin system

    Area of Science:

    • Cardiovascular Science
    • Biochemistry

    Background:

    • The role of prostaglandins in myocardial ischemia is not fully understood.
    • Factors influencing thromboxane A2 and prostacyclin balance are critical in cardiovascular events.

    Purpose of the Study:

    • To review the current understanding of the prostaglandin system in myocardial ischemia.
    • To discuss strategies targeting thromboxane A2 and prostacyclin for preventing platelet aggregation.

    Main Methods:

    • Literature review of studies on prostaglandin system, myocardial ischemia, and platelet aggregation.
    • Analysis of factors affecting thromboxane A2 and prostacyclin production.
    • Evaluation of therapeutic strategies targeting these pathways.

    Main Results:

    • Evidence suggests the prostaglandin system significantly impacts myocardial ischemia.
    • Imbalances in thromboxane A2 and prostacyclin promote vasoconstriction and thrombosis.
    • Interventions targeting thromboxane A2 and prostacyclin are under investigation.

    Conclusions:

    • Further research is needed to clarify the prostaglandin system's role in myocardial ischemia.
    • Careful clinical trials are essential to validate therapeutic strategies involving prostaglandins.
    • Long-term observations are crucial to ensure the net benefit of prostaglandin-based interventions.

    More Related Videos

    A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis04:30

    A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

    Published on: May 14, 2013

    27.4K
    Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery09:41

    Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

    Published on: December 23, 2014

    16.1K

    Related Concept Videos

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

    Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
    Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
    1.6K
    Ischemic Heart Disease: Overview01:17

    Ischemic Heart Disease: Overview

    Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
    Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
    3.8K
    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

    Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
    These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
    613
    Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

    Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

    The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
    Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
    1.7K
    Coronary Artery Disease V: Interprofessional Care01:27

    Coronary Artery Disease V: Interprofessional Care

    Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
    450
    Peripheral Artery Disease III: Interprofessional Care01:27

    Peripheral Artery Disease III: Interprofessional Care

    Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
    659